These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23247987)

  • 1. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.
    Vlaicu SI; Tegla CA; Cudrici CD; Danoff J; Madani H; Sugarman A; Niculescu F; Mircea PA; Rus V; Rus H
    Immunol Res; 2013 May; 56(1):109-21. PubMed ID: 23247987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of C5b-9 and RGC-32 in Cancer.
    Vlaicu SI; Tatomir A; Rus V; Rus H
    Front Immunol; 2019; 10():1054. PubMed ID: 31156630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane attack by complement: the assembly and biology of terminal complement complexes.
    Tegla CA; Cudrici C; Patel S; Trippe R; Rus V; Niculescu F; Rus H
    Immunol Res; 2011 Oct; 51(1):45-60. PubMed ID: 21850539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.
    Fosbrink M; Cudrici C; Tegla CA; Soloviova K; Ito T; Vlaicu S; Rus V; Niculescu F; Rus H
    Exp Mol Pathol; 2009 Apr; 86(2):87-94. PubMed ID: 19162005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription.
    Fosbrink M; Niculescu F; Rus H
    Immunol Res; 2005; 31(1):37-46. PubMed ID: 15591621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGC-32' dual role in smooth muscle cells and atherogenesis.
    Vlaicu SI; Tatomir A; Fosbrink M; Nguyen V; Boodhoo D; Cudrici C; Badea TC; Rus V; Rus H
    Clin Immunol; 2022 May; 238():109020. PubMed ID: 35462050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the C5b-9 complement complex in cell cycle and apoptosis.
    Rus HG; Niculescu FI; Shin ML
    Immunol Rev; 2001 Apr; 180():49-55. PubMed ID: 11414362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.
    Yu T; Wang L; Zhao C; Qian B; Yao C; He F; Zhu Y; Cai M; Li M; Zhao D; Zhang J; Wang Y; Qiu W
    J Cell Mol Med; 2019 Aug; 23(8):5654-5671. PubMed ID: 31184423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase.
    Niculescu F; Badea T; Rus H
    Atherosclerosis; 1999 Jan; 142(1):47-56. PubMed ID: 9920505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of complement activation in atherogenesis: the first 40 years.
    Vlaicu SI; Tatomir A; Rus V; Mekala AP; Mircea PA; Niculescu F; Rus H
    Immunol Res; 2016 Feb; 64(1):1-13. PubMed ID: 26091721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway.
    Soane L; Cho HJ; Niculescu F; Rus H; Shin ML
    J Immunol; 2001 Aug; 167(4):2305-11. PubMed ID: 11490019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.
    Fosbrink M; Niculescu F; Rus V; Shin ML; Rus H
    J Biol Chem; 2006 Jul; 281(28):19009-18. PubMed ID: 16670089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent.
    Niculescu F; Rus H; van Biesen T; Shin ML
    J Immunol; 1997 May; 158(9):4405-12. PubMed ID: 9127005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration.
    Vlaicu SI; Tatomir A; Boodhoo D; Ito T; Fosbrink M; Cudrici C; Mekala AP; Ciriello J; Crişan D; Boţan E; Rus V; Rus H
    Exp Mol Pathol; 2016 Oct; 101(2):221-230. PubMed ID: 27619159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F
    Ann Med; 2005; 37(2):97-104. PubMed ID: 16026117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGC-32 and diseases: the first 20 years.
    Vlaicu SI; Tatomir A; Anselmo F; Boodhoo D; Chira R; Rus V; Rus H
    Immunol Res; 2019 Jun; 67(2-3):267-279. PubMed ID: 31250246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD.
    Hila S; Soane L; Koski CL
    Glia; 2001 Oct; 36(1):58-67. PubMed ID: 11571784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase.
    Badea T; Niculescu F; Soane L; Fosbrink M; Sorana H; Rus V; Shin ML; Rus H
    J Biol Chem; 2002 Jan; 277(1):502-8. PubMed ID: 11687586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublytic terminal complement attack on myotubes decreases the expression of mRNAs encoding muscle-specific proteins.
    Lang TJ; Badea TC; Wade R; Shin ML
    J Neurochem; 1997 Apr; 68(4):1581-9. PubMed ID: 9084429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway.
    Rus H; Niculescu F; Badea T; Shin ML
    Immunopharmacology; 1997 Dec; 38(1-2):177-87. PubMed ID: 9476129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.